Lovastatin

Introduction Overview

Generic Name

lovastatin

Brand Name

Altoprev, Mevacor, Altocor

Dosage Form

oral tablet (immediate release and extended release)

Drug Class

Statins (HMG-CoA reductase inhibitors)

Pharmacokinetics

Absorption:
Lovastatin is administered orally and exhibits variable and incomplete absorption from the gastrointestinal tract. It is a prodrug that undergoes extensive first-pass metabolism primarily via the liver, limiting its systemic bioavailability to approximately 5%. Peak plasma concentrations of the active β-hydroxy acid form occur approximately 2 to 4 hours after ingestion of immediate-release tablets. The absorption is influenced by food intake; administration with meals significantly increases bioavailability, enhancing therapeutic effects. Extended-release tablets (Altoprev) provide a slow and sustained release profile to maintain therapeutic plasma concentrations over a prolonged period, improving patient compliance and lipid control.

Distribution:
Lovastatin and its active metabolites are highly protein bound (>95%), primarily to albumin. After absorption and hepatic activation, lovastatin is distributed predominantly to the liver, the primary site of action, through hepatic uptake transporters. Apparent volume of distribution ranges between 0.3 to 0.5 L/kg. Lovastatin does not significantly cross the blood-brain barrier or placenta but does distribute into maternal plasma. Its lipophilic nature aids in hepatic cell membrane penetration, which is critical for effective inhibition of HMG-CoA reductase.

Metabolism:
Lovastatin is extensively metabolized in the liver by cytochrome P450 3A4 (CYP3A4) enzymes. The prodrug form undergoes hydrolysis to the active β-hydroxyacid form, which potently inhibits HMG-CoA reductase. Metabolites primarily include hydroxylated and dealkylated forms which are less active or inactive. Drug interactions that inhibit or induce CYP3A4 can profoundly affect lovastatin plasma levels, impacting efficacy and toxicity risks, including myopathy. Polymorphisms in metabolizing enzymes and patient hepatic function also modulate metabolism.

Elimination:
Elimination of lovastatin and its metabolites occurs mainly via biliary excretion into the feces; less than 5% is excreted in urine. The elimination half-life of the active metabolites ranges from 3 to 5 hours for immediate-release forms; extended-release formulations provide prolonged systemic presence. Renal impairment does not significantly affect plasma levels; however, severe hepatic impairment can reduce clearance, leading to accumulation and increased toxicity risk. Because of enterohepatic recirculation, steady-state concentration is achieved within 3 days of consistent dosing.

Dosage Forms

Available Dosage Forms:
Lovastatin is available in both immediate-release and extended-release oral tablet formulations. Immediate-release tablets are supplied in strengths of 10 mg, 20 mg, and 40 mg. Extended-release tablets, designed for once-daily evening administration to optimize cholesterol synthesis inhibition during nocturnal hours, are provided in 20 mg, 40 mg, and 60 mg strengths.

Dosages for Adults and Adolescents:
For primary hypercholesterolemia and mixed dyslipidemia, initial dosages typically start at 10 to 20 mg once daily with the evening meal, titrated up every 4 weeks based on lipid panel response and tolerance to a maximum dose of 80 mg per day (using immediate-release formulations) or 60 mg for extended-release tablets. In patients with heterozygous familial hypercholesterolemia, dosage adjustment may be individualized as per lipid target goals. Lovastatin is not approved for use in children under 18 years.

Specific Patient Populations:
Elderly patients may be started at lower doses due to increased risk of myopathy and altered pharmacokinetics with age-associated hepatic function changes. Patients with hepatic impairment should avoid lovastatin or be monitored closely, as the drug is contraindicated in active liver disease. Renal impairment does not require dosage adjustment but careful monitoring for adverse effects is advised. Concomitant use with CYP3A4 inhibitors requires dose adjustments or alternative therapies to mitigate risk of toxic accumulation.

Mechanism Of Action

Lovastatin is a member of the statin class of lipid-lowering agents and functions primarily by competitively inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, a rate-limiting enzyme in the cholesterol biosynthesis pathway located in hepatocytes. By blocking this enzyme, lovastatin reduces the conversion of HMG-CoA to mevalonate, a critical early step in cholesterol synthesis.

This inhibition leads to reduced intracellular cholesterol levels within liver cells, triggering an upregulation of low-density lipoprotein (LDL) receptors on hepatocyte surfaces. Enhanced receptor expression increases the clearance of circulating LDL cholesterol from the plasma, thereby lowering plasma LDL cholesterol levels which are directly implicated in the pathogenesis of atherosclerosis.

At a cellular level, lovastatin also decreases the production of other downstream isoprenoids involved in intracellular signaling pathways that influence inflammatory responses, endothelial function, and plaque stability. These pleiotropic effects contribute to cardiovascular protective benefits beyond mere lipid lowering, such as improved endothelial nitric oxide production and decreased oxidative stress.

Compared to other statins, lovastatin is lipophilic, allowing it to penetrate cell membranes efficiently, but also leading to a distinct distribution profile and drug interaction potential primarily via hepatic CYP3A4 metabolism. Clinical studies have demonstrated lovastatin’s efficacy in reducing major cardiovascular events, with a safety profile consistent with the statin class. Extensive research continues into its role in modulating inflammatory and immune responses, as well as potential benefits in other lipid-related disorders.

Pharmacological Actions

Competitively inhibits HMG-CoA reductase enzyme in the cholesterol biosynthesis pathway.
Lowers plasma low-density lipoprotein (LDL) cholesterol by upregulating hepatic LDL receptors.
Reduces total cholesterol and triglyceride levels while modestly increasing high-density lipoprotein (HDL) cholesterol.
Exhibits pleiotropic effects including anti-inflammatory actions on vascular endothelium.
Improves endothelial function and nitric oxide bioavailability, contributing to cardiovascular protection.
Decreases the synthesis of isoprenoid intermediates affecting intracellular signaling.
Reduces progression of atherosclerotic plaques by stabilizing them and decreasing lipid content.
Modulates oxidative stress and immune responses involved in vascular injury.
Exerts beneficial effects on coagulation factors, decreasing thrombotic risk.
Demonstrates lipid-lowering effects effectively when combined with diet and lifestyle changes.

Therapeutic Or Clinical Uses

Treatment of primary hypercholesterolemia to reduce elevated LDL cholesterol.
Management of mixed dyslipidemia with increased cholesterol and triglycerides.
Prevention of cardiovascular events such as myocardial infarction and stroke in high-risk patients.
Reduction of coronary heart disease risk in adults with diabetes and other risk factors.
Adjunct therapy following lifestyle interventions including diet, exercise, and weight control.
Used for familial heterozygous hypercholesterolemia in patients ≥18 years.
May be utilized to slow progression of atherosclerosis in select patient populations.
Employed post-myocardial infarction to reduce recurrent ischemic events and mortality.
Off-label use in some cases of hyperlipoproteinemia Type IIa and IIb.
Potential investigational uses in inflammation-related vascular conditions and metabolic syndrome components.

Side Or Adverse Effects

Myopathy and rare cases of rhabdomyolysis potentially leading to acute renal failure.
Liver enzyme elevations and rare hepatotoxicity; periodic liver function monitoring required.
Gastrointestinal symptoms including abdominal pain, nausea, constipation, or diarrhea.
Headache and dizziness reported in some patients.
Allergic reactions ranging from mild rash to severe hypersensitivity including angioedema.
Muscle pain, tenderness, or weakness especially with fever or dark-colored urine indicating serious muscle injury.
Increased risk of muscle damage when combined with certain CYP3A4 inhibitors.
Occasional infections and respiratory symptoms noted in clinical use.
Elevations in blood glucose reported, requiring monitoring in diabetic patients.
Accidental injuries or falls noted, potentially due to muscle weakness or dizziness.
Rare cognitive disturbances including memory impairment reported anecdotally.
Fatigue and weakness can occur during therapy.
Possible joint pain and muscle cramps.
Peripheral neuropathy reported rarely.
Increased creatine kinase levels indicating muscle toxicity.

Precautions

Assess baseline liver function tests before starting therapy; avoid in active liver disease.
Monitor for signs of muscle toxicity regularly, especially in elderly and those with renal impairment.
Use caution in patients with a history of muscle disorders or hypothyroidism.
Avoid in pregnancy and breastfeeding due to potential fetal harm and transmission via breast milk.
Educate patients on symptoms of myopathy and hepatotoxicity to prompt early reporting.
Avoid excessive alcohol consumption to reduce liver injury risk.
Evaluate potential drug interactions that increase myopathy risk before initiation.
Dose adjustments may be necessary when co-administered with CYP3A4 inhibitors or inducers.
Not indicated for pediatric populations under 18 years old.
Patients with kidney disease require vigilant monitoring for adverse effects.
Temporary discontinuation advised during surgery or acute serious illness.
Maintain adherence to concomitant diet and lifestyle modifications for optimal efficacy.
Avoid grapefruit and grapefruit products that inhibit metabolism and increase toxicity risk.
Use effective contraception in women of childbearing potential during treatment.
Monitor blood glucose in diabetic patients, as statins may increase glucose levels.

Warnings

Contraindicated in active liver disease and unexplained persistent elevations of hepatic transaminases.
Pregnancy Category X: must stop lovastatin if pregnancy is detected due to teratogenic risk.
Potential for severe muscle damage (rhabdomyolysis) causing renal failure; discontinue if symptoms develop.
Use with caution when combined with drugs known to raise risk of myopathy (e.g., certain antifungals, macrolide antibiotics, antivirals).
Periodic monitoring of liver function and creatine kinase recommended during therapy.
Risk of myopathy increased in patients with renal impairment or hypothyroidism.
Avoid abrupt discontinuation without physician guidance to prevent lipid level rebound.
Not recommended during breastfeeding due to potential adverse effects on the infant.
Concomitant use with cyclosporine or fibrates heightens muscle toxicity risk.
Limit alcohol intake to minimize hepatotoxicity risks.
Discontinue immediately if signs of liver injury or muscle breakdown appear.
Use caution in elderly patients who have a higher susceptibility to adverse reactions.
Avoid use with potent CYP3A4 inhibitors to prevent elevated lovastatin serum levels.
Monitor closely in patients with pre-existing neuromuscular diseases.
Inform patients about recognizing early signs of muscle problems and liver dysfunction.

Contraindication

Hypersensitivity to lovastatin or any component of the formulation.
Active hepatic disease or unexplained persistent elevations of serum transaminases.
Pregnancy and lactation due to potential teratogenic effects and toxicity.
Co-administration with strong CYP3A4 inhibitors such as certain antifungals (ketoconazole), macrolide antibiotics (erythromycin), HIV protease inhibitors, and others.
Patients with a history of statin-induced myopathy or rhabdomyolysis.
Severe renal impairment in the presence of risk factors for muscle toxicity.
Use with nefazodone is contraindicated due to increased risk of skeletal muscle toxicity.
Concomitant administration with gemfibrozil or cyclosporine is generally contraindicated owing to enhanced myopathy risk.
Not approved for individuals under 18 years of age.
Patients with active muscle disease or elevated creatine kinase prior to therapy.

Drug Interactions

CYP3A4 inhibitors (e.g., clarithromycin, erythromycin, ketoconazole, itraconazole, posaconazole, voriconazole) increase lovastatin plasma levels and risk of myopathy.
Antiviral agents for HIV or hepatitis C (boceprevir, cobicistat, dasabuvir, elvitegravir, indinavir, lopinavir/ritonavir, nelfinavir, ombitasvir, paritaprevir, saquinavir, telaprevir, tipranavir) potentiate lovastatin toxicity risk.
Concurrent use with fibrates (gemfibrozil, fenofibrate, fenofibric acid) increases the risk of muscle damage.
Niacin-containing medications increase risk of statin-related adverse effects, especially myopathy.
Cyclosporine elevates lovastatin concentrations leading to increased muscle and liver toxicity.
Danazol co-administration heightens risk of myopathy.
Caution with warfarin as lovastatin can potentiate anticoagulant effects, requiring INR monitoring.
Interactions with grapefruit juice inhibit CYP3A4 metabolism causing elevated lovastatin levels.
Rifampin induces CYP3A4 enzymes potentially decreasing lovastatin efficacy.
Colchicine combined with lovastatin may increase risk of muscle toxicity.
Certain anticonvulsants may alter statin metabolism.
Concomitant use of other lipid-lowering therapies requires monitoring for additive side effects.
Phenytoin can affect plasma levels of lovastatin due to hepatic enzyme induction.
Drugs affecting P-glycoprotein transporters may modify lovastatin exposure.
Herbal supplements such as St. John's Wort may reduce statin efficacy via CYP induction.

Preparations Of The Drug

Immediate-release oral tablets available in 10 mg, 20 mg, and 40 mg strengths (e.g., Mevacor).
Extended-release oral tablets available in 20 mg, 40 mg, and 60 mg strengths designed for once-daily bedtime dosing (e.g., Altoprev, Altocor).
Tablets formulated for oral administration to be swallowed whole without crushing or chewing.
Supplied in blister packs or bottles stored at controlled room temperature away from moisture, heat, and light.
Packaging includes patient information leaflets detailing dosing, side effects, and precautions.
Available as prescription-only medications requiring careful titration and monitoring.
Extended-release formulations improve patient adherence by providing sustained lipid lowering.
Standard formulations do not include pediatric dosing; specific compounding may be needed for research use.
Tablets are film-coated to mask taste and improve stability.
Available globally with varying brand names and manufacturing sources but consistent bioequivalence.